121 related articles for article (PubMed ID: 28648122)
21. Effect of cyp2d6*10 allele on the pharmacokinetics of loratadine in chinese subjects.
Yin OQ; Shi XJ; Tomlinson B; Chow MS
Drug Metab Dispos; 2005 Sep; 33(9):1283-7. PubMed ID: 15932952
[TBL] [Abstract][Full Text] [Related]
22. Cytochrome P450 2D6*10 genotype affects the pharmacokinetics of dimemorfan in healthy Chinese subjects.
Pei Q; Peng J; Tan H; Yang L; Yang X; Liu L; Liu S; Yuan H; Yang G
Eur J Drug Metab Pharmacokinet; 2015 Dec; 40(4):427-33. PubMed ID: 25159483
[TBL] [Abstract][Full Text] [Related]
23. The effects of tramadol on static and dynamic pupillometry in healthy subjects--the relationship between pharmacodynamics, pharmacokinetics and CYP2D6 metaboliser status.
Fliegert F; Kurth B; Göhler K
Eur J Clin Pharmacol; 2005 Jun; 61(4):257-66. PubMed ID: 15906019
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects.
Teng R; Kujacic M; Hsia J
Clin Ther; 2014 Sep; 36(9):1217-25. PubMed ID: 25069798
[TBL] [Abstract][Full Text] [Related]
25. Effects of CYP2D6 Genetic Polymorphism and Drug Interaction on the Metabolism of Dacomitinib.
Han M; Zhang X; Ye Z; Wang J; Kong Q; Hu X; Qian J; Cai J; Hu G
Chem Res Toxicol; 2022 Feb; 35(2):265-274. PubMed ID: 34936353
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic and tolerability profile of pridopidine in healthy-volunteer poor and extensive CYP2D6 metabolizers, following single and multiple dosing.
Lindskov Krog P; Osterberg O; Gundorf Drewes P; Rembratt Å; Schultz A; Timmer W
Eur J Drug Metab Pharmacokinet; 2013 Mar; 38(1):43-51. PubMed ID: 22948856
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes.
Yue QY; Zhong ZH; Tybring G; Dalén P; Dahl ML; Bertilsson L; Sjöqvist F
Clin Pharmacol Ther; 1998 Oct; 64(4):384-90. PubMed ID: 9797795
[TBL] [Abstract][Full Text] [Related]
28. A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.
Reckamp KL; Giaccone G; Camidge DR; Gadgeel SM; Khuri FR; Engelman JA; Koczywas M; Rajan A; Campbell AK; Gernhardt D; Ruiz-Garcia A; Letrent S; Liang J; Taylor I; O'Connell JP; Jänne PA
Cancer; 2014 Apr; 120(8):1145-54. PubMed ID: 24501009
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and bioavailability comparison of generic and branded citalopram 20 mg tablets: an open-label, randomized-sequence, two-period crossover study in healthy Chinese CYP2C19 extensive metabolizers.
Jiang T; Rong Z; Xu Y; Chen B; Xie Y; Chen C; Lu Y; Shen Y; Li H; Sun J; Chen H
Clin Drug Investig; 2013 Jan; 33(1):1-9. PubMed ID: 23179471
[TBL] [Abstract][Full Text] [Related]
30. Effects of the Chinese herbal formula "Zuojin Pill" on the pharmacokinetics of dextromethorphan in healthy Chinese volunteers with CYP2D6*10 genotype.
Qiu F; Liu S; Miao P; Zeng J; Zhu L; Zhao T; Ye Y; Jiang J
Eur J Clin Pharmacol; 2016 Jun; 72(6):689-95. PubMed ID: 27023460
[TBL] [Abstract][Full Text] [Related]
31. Quantitative bioanalytical assay for the human epidermal growth factor receptor (HER) inhibitor dacomitinib in rat plasma by UPLC-MS/MS.
Qiu X; Lin Q; Ning Z; Qian X; Li P; Ye L; Xie S
J Pharm Biomed Anal; 2019 Mar; 166():66-70. PubMed ID: 30612075
[TBL] [Abstract][Full Text] [Related]
32. Effects of CYP3A5 and CYP2D6 genetic polymorphism on the pharmacokinetics of diltiazem and its metabolites in Chinese subjects.
Zheng T; Su CH; Zhao J; Zhang XJ; Zhang TY; Zhang LR; Kan QC; Zhang SJ
Pharmazie; 2013 Apr; 68(4):257-60. PubMed ID: 23700791
[TBL] [Abstract][Full Text] [Related]
33. Tolerability and pharmacokinetics of ranolazine following single and multiple sustained-release doses in Chinese healthy adult volunteers: a randomized, open-label, Latin square design, phase I study.
Tan QY; Li HD; Zhu RH; Zhang QZ; Zhang J; Peng WX
Am J Cardiovasc Drugs; 2013 Feb; 13(1):17-25. PubMed ID: 23355361
[TBL] [Abstract][Full Text] [Related]
34. Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study.
Nieminen T; Uusitalo H; Mäenpää J; Turjanmaa V; Rane A; Lundgren S; Ropo A; Rontu R; Lehtimäki T; Kähönen M
Eur J Clin Pharmacol; 2005 Dec; 61(11):811-9. PubMed ID: 16315032
[TBL] [Abstract][Full Text] [Related]
35. Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers.
Cai WM; Chen B; Zhou Y; Zhang YD
Clin Pharmacol Ther; 1999 Nov; 66(5):516-21. PubMed ID: 10579479
[TBL] [Abstract][Full Text] [Related]
36. The impact of CYP2D6 polymorphisms on the pharmacokinetics of codeine and its metabolites in Mongolian Chinese subjects.
Wu X; Yuan L; Zuo J; Lv J; Guo T
Eur J Clin Pharmacol; 2014 Jan; 70(1):57-63. PubMed ID: 24077935
[TBL] [Abstract][Full Text] [Related]
37. CYP3A5 but not CYP2D6 polymorphism contributes significantly to the variability in dextropropoxyphene disposition.
Yin OQ; Tomlinson B; Chow MS
J Clin Pharmacol; 2010 Oct; 50(10):1136-41. PubMed ID: 20133509
[TBL] [Abstract][Full Text] [Related]
38. Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam.
Veiga MI; Asimus S; Ferreira PE; Martins JP; Cavaco I; Ribeiro V; Hai TN; Petzold MG; Björkman A; Ashton M; Gil JP
Eur J Clin Pharmacol; 2009 Apr; 65(4):355-63. PubMed ID: 18979093
[TBL] [Abstract][Full Text] [Related]
39. Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia.
Wang Y; Zhou L; Dutreix C; Leroy E; Yin Q; Sethuraman V; Riviere GJ; Yin OQ; Schran H; Shen ZX
Br J Clin Pharmacol; 2008 Jun; 65(6):885-92. PubMed ID: 18384443
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial.
Park K; Cho BC; Kim DW; Ahn MJ; Lee SY; Gernhardt D; Taylor I; Campbell AK; Zhang H; Giri N; Letrent SP; O'Connell J; Heo DS
J Thorac Oncol; 2014 Oct; 9(10):1523-31. PubMed ID: 25521398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
